Toggle Nav
My Cart
Search
Advanced Search
Menu
Account
Settings

Advancements in miRNA: Technology Assessment

Advancements in miRNA: Technology Assessment

Developments in miRNA sequencing and analysis are driving future growth potential in therapeutics and diagnostics

RELEASE DATE
29-Aug-2022
REGION
Global
Deliverable Type
Technology Research
Research Code: DA64-01-00-00-00
SKU: HC03580-GL-TR_26854
AvailableYesPDF Download
$4,950.00
In stock
SKU
HC03580-GL-TR_26854

Advancements in miRNA: Technology Assessment
Published on: 29-Aug-2022 | SKU: HC03580-GL-TR_26854

Need more details?
$4,950.00
DownloadLink
Request Sample
Add to Compare
Need more details?
Description

Accelerated research around RNA-based therapeutics and diagnostics, accompanied by technology advancements in sequencing the human genome, has resulted in a better understanding of the role of miRNA in biological pathways, enhancing its potential in both therapeutics and diagnostics. The successful clinical validation of miRNA diagnostic tests has created several opportunities for miRNA diagnostic companies. The role of miRNAs as circulating biomarkers makes it possible to perform diagnostics from body fluids. The potential of miRNA biomarkers in identifying diseases like thyroid cancer, breast cancer, and ovarian cancer is being explored. miRNA diagnostics is expected to grow further and become prominent in point-of-care diagnostics. The development of miRNA therapeutics has had its challenges with respect to stability and delivery issues. However, newer approaches in the development of antagomiRs (miRNA inhibiting drugs) and agomiRs (miRNA replacement therapy) have shown promising results. miRNA companies have witnessed a highly competitive ecosystem and have been acquired by several larger pharma and diagnostics companies upon their entry into the clinical trial stage.

This study focuses on the developments in miRNA therapeutics and diagnostics. It identifies the factors driving interest in miRNA research as well as those affecting the commercialization of miRNA therapeutics and diagnostics. The report also discusses the emerging opportunities for miRNA technology companies and highlights investment prospects for industry participants and stakeholders.

Infographic
Table of Contents

Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on miRNA Technology Growth

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Micro Ribonucleic Acid (miRNA) Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Research Methodology

Scope of Analysis

Segmentation

Growth Drivers

Growth Restraints

Emerging Trends in miRNA Therapeutics and Diagnostics

Increasing Research in miRNA Therapeutics and Diagnostics

miRNA Drugs Experiencing Rapid Strides in Clinical Development

Enablers Accelerating miRNA Research and Commercial Development

Introduction to miRNA Therapeutics

miRNA Therapeutics to Address Complex Diseases

Evolving Approaches in Developing Antagomirs and miRNA Mimics

Structural Modifications to Increase miRNA Stability

Application of miRNAs in Diseases

Oncology

Respiratory Diseases

Neurology

Cardiovascular Diseases

Other Diseases

Other Diseases

miRNA Therapeutics in Development by Companies

Increasing miRNA Research Activities in Academia

Challenges in miRNA Therapeutics

Important miRNA Therapeutics Delivery Systems

Comparison of miRNA Delivery Systems

Developing Newer Delivery Systems

Future Prospects of miRNA Therapeutics

Introduction to miRNA Diagnostics

Benefits of miRNA Diagnostics

Opportunities for Using miRNA in Diagnostics

Emerging Developments in miRNA Diagnostics

Oncology

Neurological Diseases

Cardiovascular and Other Diseases

M&A miRNA Therapeutics

M&A miRNA Diagnostics

Funding Landscape of miRNA companies

miRNA—Important Takeaways

miRNA—Important Takeaways

Growth Opportunity 1: Improved Targeted Delivery Systems to Reduce Off-target Effects and Toxicity

Growth Opportunity 1: Improved Targeted Delivery Systems to Reduce Off-target Effects and Toxicity (continued)

Growth Opportunity 2:Development of POC Diagnostics to Detect Circulating Biomarkers Across Diseases 

Growth Opportunity 2: Development of POC Diagnostics to Detect Circulating Biomarkers Across Diseases (continued)

Growth Opportunity 3: Companion Diagnostics for Precision Medicine

Growth Opportunity 3: Companion Diagnostics for Precision Medicine (continued)

Technology Readiness Levels (TRL): Explanation

Funding Landscape for miRNA Therapeutics

Funding Landscape for miRNA Therapeutics (continued) 

Funding Landscape for miRNA Diagnostics

Your Next Steps

Why Frost, Why Now?

Legal Disclaimer

Request Sample
Purchase includes:
  • Report download
  • Growth Dialog™ with our experts
Related Research
  1. Growth Opportunities in the Tissue Diagnostics Industry, Global, 2024 2029
    $4,950.00 Release Date: 26-Aug-24
  2. Molecular Diagnostics for Neurodegenerative Diseases: Technology Growth Opportunities, 2024 2028
    $4,950.00 Release Date: 19-Jun-24
  3. Precision Neurodegenerative Disease Market, Global, 2024 2028
    $2,450.00 Release Date: 26-Aug-24
  4. Diagnostics Lab Automation and Monitoring Solutions Growth Opportunities
    $4,950.00 Release Date: 17-Jun-24
  5. Smartphone-based Point-of-care Testing Innovations and Growth Opportunities
    $4,950.00 Release Date: 12-Jun-24

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Accelerated research around RNA-based therapeutics and diagnostics, accompanied by technology advancements in sequencing the human genome, has resulted in a better understanding of the role of miRNA in biological pathways, enhancing its potential in both therapeutics and diagnostics. The successful clinical validation of miRNA diagnostic tests has created several opportunities for miRNA diagnostic companies. The role of miRNAs as circulating biomarkers makes it possible to perform diagnostics from body fluids. The potential of miRNA biomarkers in identifying diseases like thyroid cancer, breast cancer, and ovarian cancer is being explored. miRNA diagnostics is expected to grow further and become prominent in point-of-care diagnostics. The development of miRNA therapeutics has had its challenges with respect to stability and delivery issues. However, newer approaches in the development of antagomiRs (miRNA inhibiting drugs) and agomiRs (miRNA replacement therapy) have shown promising results. miRNA companies have witnessed a highly competitive ecosystem and have been acquired by several larger pharma and diagnostics companies upon their entry into the clinical trial stage. This study focuses on the developments in miRNA therapeutics and diagnostics. It identifies the factors driving interest in miRNA research as well as those affecting the commercialization of miRNA therapeutics and diagnostics. The report also discusses the emerging opportunities for miRNA technology companies and highlights investment prospects for industry participants and stakeholders.
More Information
Deliverable Type Technology Research
Author Neeraja Vettekudath
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 mirna microrna
Keyword 2 microrna companies
Keyword 3 rna mirna
Podcast No
WIP Number DA64-01-00-00-00